The BTC market is small and competitive, with existing approved therapies, posing a risk despite tovecimig's unique DLL4+ targeting. Recent stock surge due to CTX-471 trial announcement ...
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary ...
Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback